The Potential Drug Interactions Between Multiple Sclerosis and COVID-19 Therapies

[摘要] Since December 2019, the coronavirus disease-2019 (COVID-19)has spread rapidly all over the world and has severely affectedthe elderly population and patients with comorbidities. Druginteractions with agents used in the treatment of multiplesclerosis (MS) such as interferon beta, glatiramer acetate,ocrelizumab, natalizumab, and alemtuzumab are rare. Therefore,interactions between disease-modifying therapies (fingolimod,teriflunomide, dimethyl fumarate, and cladribine) and COVID-19drugs1 are outlined in this letter.

[关键词] Multiple sclerosis;COVID-19;disease-modifying therapy;interaction